Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.
Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.
OCR for page 175
Oral Contraceptives & Breast Cancer F List of Background Documents For this study, the Institute of Medicine invited and commissioned reports on various topics concerning oral contraceptives and breast cancer. Four of these reports appear in this volume (Appendix A, Appendix B, Appendix D, and Appendix E). The manuscripts of eight other of these documents are available from the National Technical Information Service, 5285 Port Royal Road, Springfield, VA 22161; telephone 703-487-4650. NTIS document numbers are in parentheses. “History of Oral Contraception,” Richard A. Edgren, Director, Scientific Affairs, Syntex Laboratories, Inc., Palo Alto, Calif. (#PB91-186841) “Safety of Oral Contraception,” Richard A. Edgren, Director, Scientific Affairs, Syntex Laboratories, Inc., Palo Alto, Calif. (#PB91-186858) “The Demographics of Oral Contraceptive Use,” Jacqueline Darroch Forrest, Vice President for Research, The Alan Guttmacher Institute, New York, N.Y. (#PB91-186833) “Hormone Effects on Biological Markers in Breast Cancer,” Kenneth S. McCarty, Jr., and Kenneth S. McCarty, Sr., Departments of Biochemistry, Pathology, and Medicine, Duke University Medical Center, Durham, N.C. (#PB91-186825) “Oral Contraceptives and Breast Cancer: A Review of the Epidemio-
OCR for page 176
Oral Contraceptives & Breast Cancer logical Evidence,” Kathleen E. Malone, Department of Epidemiology, School of Public Health, University of Washington, Seattle, Wash. (Appendix A) “Summary Table of Studies of Breast Cancer Risk Related to Oral Contraceptive Use (December 11, 1989),” Kathleen E. Malone, Department of Epidemiology, School of Public Health, University of Washington, Seattle, Wash. (#PB91-186973) “Oral Contraceptives and Breast Cancer: Review of the Epidemiological Literature,” David B. Thomas, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, Wash. (Appendix B) “Age-Specific Differences in the Relationship Between Oral Contraceptive Use and Breast Cancer,” Phyllis A. Wingo, Nancy C. Lee, Howard W. Ory, Valerie Beral, Herbert B. Peterson, and P. Rhoades, Centers for Disease Control, Atlanta, Ga. (#PB91-186551) “Animal Models of Sex Steroid Hormones and Mammary Cancer: Are There Lessons for Our Understanding of Studies in Humans?” Diana B. Petitti, Department of Family and Community Medicine, University of California School of Medicine, San Francisco, Calif. (Appendix D) “Risks and Benefits of Oral Contraceptives: Will Breast Cancer Tip the Balance?” David C. G. Skegg, Department of Preventive and Social Medicine, University of Otago, Dunedin, New Zealand. (Appendix E) “Oral Contraceptives and Breast Cancer: Issues Related to Age, Duration of Use, Dose, and Latent Effects,” James J. Schlesselman, Department of Preventive Medicine and Biometrics, School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Md. (#PB91-186569) “Modeling Risks and Benefits of Oral Contraceptives,” Judith Fortney and Michele Bonhomme, Division of Reproductive Epidemiology and Sexually Transmitted Diseases, Family Health International, Research Triangle Park, N.C. (#PB91-186817)
Representative terms from entire chapter: